This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n9http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F13%3A10145974%21RIV14-MZ0-00179906/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F13%3A10145974%21RIV14-MZ0-00179906
rdf:type
n15:Vysledek skos:Concept
rdfs:seeAlso
http://www.academicjournals.org/article/article1380887808_Karasova%20et%20al.pdf
dcterms:description
Although the information about Alzheimer's disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about real drug concentration in the brain or timedependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, highperformance liquid chromatography (HPLC) method with special (IAM - immobilized artificial membrane) column was used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules are able to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecules probably use passive transport to permeate into the central nervous system; tacrine and 7- methoxytacrine exert the highest passive permeation from this set of compounds. Although the information about Alzheimer's disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about real drug concentration in the brain or timedependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, highperformance liquid chromatography (HPLC) method with special (IAM - immobilized artificial membrane) column was used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules are able to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecules probably use passive transport to permeate into the central nervous system; tacrine and 7- methoxytacrine exert the highest passive permeation from this set of compounds.
dcterms:title
Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study
skos:prefLabel
Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study Acetylcholinesterase inhibitors used or tested in Alzheimer's disease therapy; their passive diffusion through blood brain barrier: In vitro study
skos:notation
RIV/00179906:_____/13:10145974!RIV14-MZ0-00179906
n15:predkladatel
n16:ico%3A00179906
n3:aktivita
n19:I n19:P
n3:aktivity
I, P(GAP303/11/1907), P(GAP303/12/0611)
n3:cisloPeriodika
22
n3:dodaniDat
n7:2014
n3:domaciTvurceVysledku
n4:6306888 n4:8866651
n3:druhVysledku
n20:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
59334
n3:idVysledku
RIV/00179906:_____/13:10145974
n3:jazykVysledku
n18:eng
n3:klicovaSlova
Alzheimer disease; acetylcholinesterase; central nervous system; Blood-brain barrier
n3:klicoveSlovo
n14:acetylcholinesterase n14:central%20nervous%20system n14:Alzheimer%20disease n14:Blood-brain%20barrier
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[D2C03A715898]
n3:nazevZdroje
African Journal of Pharmacy and Pharmacology
n3:obor
n8:FR
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
5
n3:projekt
n11:GAP303%2F12%2F0611 n11:GAP303%2F11%2F1907
n3:rokUplatneniVysledku
n7:2013
n3:svazekPeriodika
7
n3:tvurceVysledku
Žďárová Karasová, Jana Korábečný, Jan Kuča, Kamil Zemek, Filip Šepsová, Vendula
s:issn
1996-0816
s:numberOfPages
11
n9:doi
10.5897/AJPP2013.2977